April 3 (Reuters) - GlaxoSmithKline plc GSK.L said on Friday its treatment for a chronic inflammatory disease of the nasal passage linings or sinuses met the main goals in a late-stage study.
The treatment, Nucala, was tested in patients who had a history of previous surgery and were in need of further surgery due to severe symptoms or worsening of the condition, the British drugmaker said. (https://bit.ly/2UZbeap)
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Vinay Dwivedi)
((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.